Trial Profile
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Cisplatin; Gemcitabine
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 21 Jul 2006 New trial record.